$116.81
00.00%
Pre-Market: 5:08 PM EDT
15 minutes delayed
Comments
Loading...
Blueprint Medicines
BPMCNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Blueprint Medicines (NASDAQ:BPMC) Stock, Analyst Ratings, Price Targets, Forecasts
Blueprint Medicines Corp has a consensus price target of $105.36 based on the ratings of 22 analysts. The high is $168 issued by Goldman Sachs on May 6, 2024. The low is $43 issued by SVB Leerink on June 5, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, Oppenheimer, and Needham on July 12, 2024, July 8, 2024, and June 28, 2024, respectively. With an average price target of $123.33 between Morgan Stanley, Oppenheimer, and Needham, there's an implied 5.58% upside for Blueprint Medicines Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Oppenheimer
Needham
JMP Securities
Stephens & Co.
1calculated from analyst ratings
Analyst Ratings for Blueprint Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/12/2024 | Buy Now | -1.55% | Morgan Stanley | Michael Ulz | $110 → $115 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 7.01% | Oppenheimer | Matthew Biegler | $114 → $125 | Maintains | Outperform | Get Alert |
| 06/28/2024 | Buy Now | 11.29% | Needham | Ami Fadia | $130 → $130 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 7.01% | JMP Securities | Reni Benjamin | $125 → $125 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/14/2024 | Buy Now | 19.85% | Stephens & Co. | Sudan Loganathan | → $140 | Initiates | → Overweight | Get Alert |
| 05/06/2024 | Buy Now | -16.96% | Leerink Partners | Andrew Berens | $50 → $97 | Upgrade | Underperform → Market Perform | Get Alert |
| 05/06/2024 | Buy Now | 43.82% | Goldman Sachs | Terence Flynn | $121 → $168 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -34.94% | Citigroup | David Lebowitz | $65 → $76 | Maintains | Sell | Get Alert |
| 05/03/2024 | Buy Now | 15.57% | HC Wainwright & Co. | Andrew Fein | $125 → $135 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 7.01% | JMP Securities | Reni Benjamin | $114 → $125 | Maintains | Market Outperform | Get Alert |
| 05/03/2024 | Buy Now | -35.79% | Barclays | Peter Lawson | $70 → $75 | Maintains | Equal-Weight | Get Alert |
| 05/03/2024 | Buy Now | -10.97% | Piper Sandler | Christopher Raymond | $78 → $104 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | 11.29% | Needham | Ami Fadia | $97 → $130 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -16.96% | Needham | Ami Fadia | → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 7.01% | HC Wainwright & Co. | Andrew Fein | → $125 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | -5.83% | Wedbush | David Nierengarten | → $110 | Reiterates | Outperform → Outperform | Get Alert |
| 04/26/2024 | Buy Now | -16.96% | Needham | Ami Fadia | → $97 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | 11.29% | Stifel | Bradley Canino | $120 → $130 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/26/2024 | Buy Now | -16.96% | Needham | Ami Fadia | → $97 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/16/2024 | Buy Now | -44.35% | Citigroup | David Lebowitz | $54 → $65 | Maintains | Sell | Get Alert |
| 02/13/2024 | Buy Now | -40.07% | Barclays | Peter Lawson | $58 → $70 | Maintains | Equal-Weight | Get Alert |
| 01/16/2024 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/09/2024 | Buy Now | -16.96% | Stifel | Bradley Canino | $95 → $97 | Maintains | Buy | Get Alert |
| 12/22/2023 | Buy Now | -14.39% | Raymond James | Dane Leone | $85 → $100 | Maintains | Strong Buy | Get Alert |
| 12/19/2023 | Buy Now | -1.55% | Wells Fargo | Derek Archila | $86 → $115 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | -27.23% | HC Wainwright & Co. | Andrew Fein | → $85 | Reiterates | Buy → Buy | Get Alert |
| 10/27/2023 | Buy Now | -27.23% | Oppenheimer | Matthew Biegler | → $85 | Upgrade | Perform → Outperform | Get Alert |
| 10/27/2023 | Buy Now | -46.07% | Morgan Stanley | Michael Ulz | $59 → $63 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -50.35% | Barclays | Peter Lawson | $46 → $58 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -36.65% | Needham | Ami Fadia | $66 → $74 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | -43.5% | Needham | Ami Fadia | $65 → $66 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/03/2023 | Buy Now | -49.49% | Morgan Stanley | Michael Ulz | $55 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | -28.94% | Goldman Sachs | Terence Flynn | $93 → $83 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -44.35% | Needham | Ami Fadia | → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | -27.23% | HC Wainwright & Co. | Andrew Fein | → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -44.35% | Needham | Ami Fadia | → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | — | Wells Fargo | Derek Archila | $55 → $83 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 07/14/2023 | Buy Now | -52.91% | Morgan Stanley | Michael Ulz | $55 → $55 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | -52.91% | Wells Fargo | Derek Archila | $48 → $55 | Maintains | Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | -63.19% | SVB Leerink | Andrew Berens | $48 → $43 | Downgrade | Market Perform → Underperform | Get Alert |
| 05/23/2023 | Buy Now | -29.8% | Guggenheim | Michael Schmidt | $78 → $82 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -35.79% | Wedbush | Liana Moussatos | → $75 | Reiterates | Outperform → Outperform | Get Alert |
| 05/23/2023 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/23/2023 | Buy Now | -58.91% | Wells Fargo | Derek Archila | $47 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/23/2023 | Buy Now | -27.23% | HC Wainwright & Co. | Andrew Fein | $75 → $85 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -42.64% | Needham | Ami Fadia | $65 → $67 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -60.62% | Barclays | Peter Lawson | $44 → $46 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -52.91% | Morgan Stanley | Michael Ulz | $50 → $55 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | — | Reiterates | → Market Outperform | Get Alert |
| 05/05/2023 | Buy Now | -35.79% | HC Wainwright & Co. | Andrew Fein | $70 → $75 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | -44.35% | Needham | Ami Fadia | $56 → $65 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | -51.2% | Needham | Ami Fadia | → $57 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | → Market Outperform | Get Alert |
| 02/28/2023 | Buy Now | -2.41% | JMP Securities | Benjamin Chaiken | → $114 | Reiterates | → Market Perform | Get Alert |
| 02/28/2023 | Buy Now | -51.2% | Needham | Ami Fadia | → $57 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -40.07% | HC Wainwright & Co. | Andrew Fein | → $70 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | -51.2% | Needham | Ami Fadia | → $57 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -67.47% | SVB Leerink | Andrew Berens | $45 → $38 | Maintains | Market Perform | Get Alert |
| 02/17/2023 | Buy Now | -27.23% | Raymond James | Dane Leone | $115 → $85 | Maintains | Strong Buy | Get Alert |
| 02/17/2023 | Buy Now | -40.07% | HC Wainwright & Co. | Andrew Fein | → $70 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | -51.2% | Needham | Ami Fadia | $60 → $57 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | -48.63% | Needham | Ami Fadia | → $60 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | -48.63% | Needham | Ami Fadia | → $60 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | -48.63% | Needham | Ami Fadia | → $60 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | → $114 | Reiterates | → Market Outperform | Get Alert |
| 01/27/2023 | Buy Now | -57.2% | Morgan Stanley | Michael Ulz | $75 → $50 | Maintains | Equal-Weight | Get Alert |
| 01/23/2023 | Buy Now | -62.33% | Barclays | Peter Lawson | $50 → $44 | Maintains | Equal-Weight | Get Alert |
| 01/03/2023 | Buy Now | -64.9% | Wells Fargo | Derek Archila | → $41 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | -48.63% | Needham | Ami Fadia | → $60 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | -54.63% | Barclays | Peter Lawson | $58 → $53 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | -2.41% | JMP Securities | Reni Benjamin | $152 → $114 | Maintains | Market Outperform | Get Alert |
| 11/03/2022 | Buy Now | -7.54% | Goldman Sachs | Terence Flynn | $143 → $108 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | -27.23% | Guggenheim | Michael Schmitz | $110 → $85 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | -50.35% | Barclays | Peter Lawson | $70 → $58 | Maintains | Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | -9.25% | Wedbush | Liana Moussatos | $120 → $106 | Maintains | Outperform | Get Alert |
| 11/02/2022 | Buy Now | -35.79% | Morgan Stanley | Michael Ulz | $80 → $75 | Maintains | Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | — | Oppenheimer | Matthew Biegler | — | Downgrade | Outperform → Perform | Get Alert |
| 11/02/2022 | Buy Now | -40.07% | HC Wainwright & Co. | Andrew Fein | $80 → $70 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | -55.48% | SVB Leerink | Andrew Berens | $57 → $52 | Maintains | Market Perform | Get Alert |
| 09/14/2022 | Buy Now | -22.95% | Berenberg | Zhiqiang Shu | → $90 | Initiates | → Buy | Get Alert |
| 09/09/2022 | Buy Now | -31.51% | Morgan Stanley | Michael Ulz | $65 → $80 | Maintains | Equal-Weight | Get Alert |
| 09/06/2022 | Buy Now | -22.95% | Oppenheimer | Matthew Biegler | $80 → $90 | Maintains | Outperform | Get Alert |
| 08/22/2022 | Buy Now | -28.09% | Jefferies | Eun Yang | $78 → $84 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | -14.39% | Stifel | Bradley Canino | $93 → $100 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | -51.2% | SVB Leerink | Andrew Berens | $65 → $57 | Maintains | Market Perform | Get Alert |
| 08/17/2022 | Buy Now | -64.9% | Wells Fargo | Derek Archila | $40 → $41 | Maintains | Underweight | Get Alert |
| 08/17/2022 | Buy Now | -31.51% | HC Wainwright & Co. | Andrew Fein | $100 → $80 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 22.42% | Goldman Sachs | Terence Flynn | $126 → $143 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | -44.35% | SVB Leerink | Andrew Berens | $56 → $65 | Maintains | Market Perform | Get Alert |
| 08/03/2022 | Buy Now | -1.55% | Raymond James | Dane Leone | $133 → $115 | Maintains | Strong Buy | Get Alert |
| 07/08/2022 | Buy Now | -31.51% | Oppenheimer | Matthew Biegler | → $80 | Initiates | → Outperform | Get Alert |
| 07/01/2022 | Buy Now | -52.06% | SVB Leerink | Andrew Berens | $60 → $56 | Maintains | Market Perform | Get Alert |
| 06/27/2022 | Buy Now | -65.76% | Wells Fargo | Derek Archila | → $40 | Initiates | → Underweight | Get Alert |
| 06/14/2022 | Buy Now | -44.35% | Morgan Stanley | Michael Ulz | $92 → $65 | Maintains | Equal-Weight | Get Alert |
| 06/13/2022 | Buy Now | -48.63% | SVB Leerink | Andrew Berens | $82 → $60 | Maintains | Market Perform | Get Alert |
| 06/10/2022 | Buy Now | -64.9% | Citigroup | David Lebowitz | $68 → $41 | Downgrade | Neutral → Sell | Get Alert |
| 06/01/2022 | Buy Now | -33.22% | Jefferies | Eun Yang | $88 → $78 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Blueprint Medicines (BPMC) stock?
The latest price target for Blueprint Medicines (NASDAQ:BPMC) was reported by Morgan Stanley on July 12, 2024. The analyst firm set a price target for $115.00 expecting BPMC to fall to within 12 months (a possible -1.55% downside). 40 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Blueprint Medicines (BPMC)?
The latest analyst rating for Blueprint Medicines (NASDAQ:BPMC) was provided by Morgan Stanley, and Blueprint Medicines maintained their equal-weight rating.
When was the last upgrade for Blueprint Medicines (BPMC)?
The last upgrade for Blueprint Medicines Corp happened on May 6, 2024 when Leerink Partners raised their price target to $97. Leerink Partners previously had an underperform for Blueprint Medicines Corp.
When was the last downgrade for Blueprint Medicines (BPMC)?
The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.
When is the next analyst rating going to be posted or updated for Blueprint Medicines (BPMC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.
Is the Analyst Rating Blueprint Medicines (BPMC) correct?
While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a maintained with a price target of $110.00 to $115.00. The current price Blueprint Medicines (BPMC) is trading at is $116.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.